» Articles » PMID: 39179931

Mapping Spatial Organization and Genetic Cell-state Regulators to Target Immune Evasion in Ovarian Cancer

Abstract

The drivers of immune evasion are not entirely clear, limiting the success of cancer immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to delineate immune evasion in high-grade serous tubo-ovarian cancer. To this end, we first mapped the spatial organization of high-grade serous tubo-ovarian cancer by profiling more than 2.5 million cells in situ in 130 tumors from 94 patients. This revealed a malignant cell state that reflects tumor genetics and is predictive of T cell and natural killer cell infiltration levels and response to immune checkpoint blockade. We then performed Perturb-seq screens and identified genetic perturbations-including knockout of PTPN1 and ACTR8-that trigger this malignant cell state. Finally, we show that these perturbations, as well as a PTPN1/PTPN2 inhibitor, sensitize ovarian cancer cells to T cell and natural killer cell cytotoxicity, as predicted. This study thus identifies ways to study and target immune evasion by linking genetic variation, cell-state regulators and spatial biology.

Citing Articles

Tumour-derived exosomal miR-205 promotes ovarian cancer cell progression through M2 macrophage polarization via the PI3K/Akt/mTOR pathway.

He L, Chen Q, Wu X J Ovarian Res. 2025; 18(1):28.

PMID: 39955607 PMC: 11829414. DOI: 10.1186/s13048-025-01616-3.


A quantitative spatial cell-cell colocalizations framework enabling comparisons between in vitro assembloids and pathological specimens.

Bouchard G, Zhang W, Ilerten I, Li I, Bhattacharya A, Li Y Nat Commun. 2025; 16(1):1392.

PMID: 39915493 PMC: 11802768. DOI: 10.1038/s41467-024-55129-6.


Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer.

Yeh C, Aguirre K, Laveroni O, Kim S, Wang A, Liang B Nat Immunol. 2024; 25(10):1943-1958.

PMID: 39179931 PMC: 11436371. DOI: 10.1038/s41590-024-01943-5.

References
1.
Galon J, Bruni D . Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity. 2020; 52(1):55-81. DOI: 10.1016/j.immuni.2019.12.018. View

2.
Zhao X, Shan Q, Xue H . TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2021; 22(3):147-157. DOI: 10.1038/s41577-021-00563-6. View

2.
Biswas S, Mandal G, Payne K, Anadon C, Gatenbee C, Chaurio R . IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021; 591(7850):464-470. PMC: 7969354. DOI: 10.1038/s41586-020-03144-0. View

3.
Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

4.
Leach D, Krummel M, Allison J . Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271(5256):1734-6. DOI: 10.1126/science.271.5256.1734. View